Novo walked from a monthly semaglutide pact. Ascendis keeps TransCon Sema

In Short. Novo ended its November 2024 Ascendis Transient Conjugation collaboration for metabolic disease. Licenses including once-monthly TransCon Semaglutide revert to Ascendis. The oft-cited $285 million was a deal ceiling; Ascendis filings show a $100 million upfront paid in January 2025, with the rest milestone eligibility that dies with the pact.

---

A partnership is a capital allocation claim with an exit clause. On September 14, 2026, Ascendis Pharma A/S told investors it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. The announcement follows termination of the research and development collaboration and license agreement with Novo Nordisk A/S that Ascendis announced in November 2024.

Under that agreement’s termination terms, every license Novo held in those fields reverts to Ascendis. That includes once-monthly TransCon Semaglutide, an investigational long-acting prodrug of the GLP-1 receptor agonist semaglutide. Ascendis’s Form 6-K states that neither party has any continuing financial obligations to the other.

What the $285 million figure was

When the deal was signed, Ascendis told the SEC it had potential to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program, plus sales-based milestones and tiered royalties on global net sales. The same November 4, 2024 Form 6-K said that $285 million includes an upfront fee of $100 million for the exclusive license. For each additional metabolic or cardiovascular product candidate Novo might have added, Ascendis was eligible for up to $77.5 million more in development and regulatory milestones.

Those numbers describe a deal ceiling and a payment schedule. In a later Form 6-K (filed August 13, 2026, covering results through mid-2026), Ascendis stated that the $100 million upfront was paid to the company in January 2025. The remainder of the $285 million was eligibility for development and regulatory milestones that fall away with termination. Collapsing the full headline into cash already received turns a ceiling into a receipt.

Novo had the contractual right to terminate without cause. Ascendis’s 2024 deal filing said so explicitly. Fierce Biotech reported that a Novo spokesperson declined to detail why the company walked, and still described less-frequent injections than current marketed options as an R&D focus pursued internally and with external partners.

Who owns the asset tomorrow

Fierce, writing through Ascendis’s September 14 release, says the company will itself pursue TransCon Semaglutide, a once-monthly prodrug of semaglutide. CEO Jan Mikkelsen said Ascendis now plans to initiate multiple new programs in cardiovascular and metabolic diseases, including obesity. Those are statements of intent and ownership. Public filings opened for this draft do not report Phase 1 or Phase 2 efficacy results for the monthly prodrug, so none are claimed here.

TransCon (Transient Conjugation) is Ascendis’s platform for temporarily linking an inert carrier to a parent drug. The company already sells TransCon products in endocrinology. The Novo collaboration was the metabolic franchise bet layered on that platform. When the partner exits, the platform and TransCon Semaglutide stay with Ascendis; Novo’s commercial engine for a monthly Wegovy-class molecule leaves with the partner.

Timing next to a rebrand

The walk-away landed the morning after Novo’s everyday branding dropped “Nordisk” while the legal name Novo Nordisk A/S stayed put. Fierce and BioSpace covered the rebrand as a separate corporate-identity story. That rebrand is calendar context, not the capital event. The capital questions are who paid what, who keeps TransCon Semaglutide, and which milestone promises expire when a collaboration ends.

Read the next “$X million biobucks” headline the same way. Ask for the upfront that cleared, the milestones still contingent, and the clause that lets either side walk. Ascendis’s filings answer those three questions for this deal. The once-monthly semaglutide prodrug remains Ascendis’s to prove.